相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting the epidermal growth factor receptor in metastatic colorectal cancer
Kimmie Ng et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
From human genetics and genomics to pharmacogenetics and pharmacogenomics: Past lessons, future directions
Daniel W. Nebert et al.
DRUG METABOLISM REVIEWS (2008)
The Environmental Genome Project: Reference polymorphisms for drug metabolism genes and genome-wide association studies
Mark J. Rieder et al.
DRUG METABOLISM REVIEWS (2008)
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
Mark I. McCarthy et al.
NATURE REVIEWS GENETICS (2008)
Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia cancer agency experience
Kenneth S. Wilson et al.
CANCER INVESTIGATION (2007)
Determination of ERCC2 Lys751 Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients:: relationships with treatment outcome
Valerie Le Morvan et al.
PHARMACOGENOMICS (2007)
Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway
Laurence Gamelin et al.
CLINICAL CANCER RESEARCH (2007)
FCGR2A and FCGR3A Polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
Wu Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer
Wu Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
Andrea Sartore-Bianchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
W. Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
Jean-Francois Cote et al.
CLINICAL CANCER RESEARCH (2007)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
Annamaria Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation
Salvatore Terrazzino et al.
PHARMACOGENETICS AND GENOMICS (2006)
Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
Kwang Wook Suh et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen
Wataru Ichikawa et al.
CLINICAL CANCER RESEARCH (2006)
Statistical power of association using the extreme discordant phenotype design
Ge Zhang et al.
PHARMACOGENETICS AND GENOMICS (2006)
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy
Thierry Lecomte et al.
CLINICAL CANCER RESEARCH (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Tumor thymidylate synthase 1494de16 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment
E Dotor et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy
C Massacesi et al.
CANCER (2006)
Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation
MA Gordon et al.
PHARMACOGENOMICS (2006)
Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
E Marcuello et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Pharmacogenetics of colorectal cancer
S Marsh
EXPERT OPINION ON PHARMACOTHERAPY (2005)
Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil
E Hitre et al.
PHARMACOGENETICS AND GENOMICS (2005)
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
J Viguier et al.
CLINICAL CANCER RESEARCH (2005)
Measuring the value of pharmacogenomics
KA Phillips et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
DM Kweekel et al.
CANCER TREATMENT REVIEWS (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer
KW Suh et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity
A Jakobsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology
Y Zhu et al.
CANCER RESEARCH (2004)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A review of oxaliplatin and its clinical use in colorectal cancer
A Grothey et al.
EXPERT OPINION ON PHARMACOTHERAPY (2004)
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy
T Lecomte et al.
CLINICAL CANCER RESEARCH (2004)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
Single nucleotide polymorphism in the 5′ tandem repeat sequences of Thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients
E Marcuello et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients
MC Etienne et al.
PHARMACOGENETICS (2004)
Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
WE Evans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cellular and molecular aspects of drugs of the future: oxaliplatin
AM Di Francesco et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2002)
Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli
TM Ishimoto et al.
PHARMACOGENETICS (2002)
Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy:: Phenotypic and genotypic analyses
MC Etienne et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Acute oxaliplatin-induced peripheral nerve hyperexcitability
RH Wilson et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice
L Iyer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Thymidylate synthase expression in colorectal cancer:: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy
D Edler et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer
DJ Park et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2002)
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
Y Shirota et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China
SJ London et al.
LANCET (2000)
XPD polymorphisms: effects on DNA repair proficiency
RM Lunn et al.
CARCINOGENESIS (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Advances in pharmacogenetics and pharmacogenomics
ES Vesell
JOURNAL OF CLINICAL PHARMACOLOGY (2000)
分享论文
